Table of Content


Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I - Overview
Neurofibromatoses Type I - Therapeutics Development
Neurofibromatoses Type I - Therapeutics Assessment
Neurofibromatoses Type I - Companies Involved in Therapeutics Development
Neurofibromatoses Type I - Drug Profiles
Neurofibromatoses Type I - Dormant Projects
Neurofibromatoses Type I - Discontinued Products
Neurofibromatoses Type I - Product Development Milestones
Appendix



List of Figures

List of Figures
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Advenchen Laboratories LLC, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AlloMek Therapeutics, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Bristol-Myers Squibb Co, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Eli Lilly and Co, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Fochon Pharmaceutical Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Healx Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by NFlection Therapeutics Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Novartis AG, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Ono Pharmaceutical Co Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Pfizer Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Sino Biopharmaceutical Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by SpringWorks Therapeutics Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Vyriad Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, 2021